What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Blood-based NfL - A biomarker for differential diagnosis of parkinsonian disorder
Neurol 88:930-937,922, Hansson, O.,et al, 2017
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Early Weight Loss in Parkinsonism Predicts Poor Outcomes
Neurol 89:2254-2261, Cumming, K.,et al, 2017
Exploring the Association Between Rosacea and Parkinson Disease
JAMA Neurol 73:529-534, Egeberg, A.,et al, 2016
Parkinsons Disease Beyond 20 Years
JNNP 86:849-855, Cilia, R.,et al, 2015
Long-Term Clinical Outcomes After Fetal Cell Transplantation in Parkinson Disease Implications for the Future of Cell Therapy
JAMA 311:617-618, Bega, D. & Krainc, D., 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011
Pallidal Versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease
NEJM 362:2077-2091, Pollett,K.A., et al, 2010
A Meta-Regression of the Long-Term Effects of Deep Brain Stimulation on Balance and Gait in PD
Neurol 75:1292-1299, St. George,R.J.,et al, 2010
Increased Risk of Parkinsonism in Women Who Underwent Oophorectomy Before Menopause
Neurol 70:200-209, Rocca,W.A.,et al, 2008
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Dementia and Survival in Parkinson Disease: A 12-Year Population Study
Neurol 70:1017-1022, Buter,T.C.,et al, 2008
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Serum Uric Acid and Clinical Progression in Parkinson Disease: Potential Biomarker for Nigrostriatal Failure
Arch Neurol 65:698-699, Schiess,M. &Oh,I., 2008
Attempted and Completed Suicides After Subthalamic Nucleus Stimulation for Parkinsons Disease
JNNP 79:952-954, Soulas,T.,et al., 2008
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Advanced Parkinson Disease Treated with Rotigotine Transdermal System PREFER Study
Neurol 68:1262-1267, LeWitt,P.A.,et al, 2007
Is DBS-STN Appropriate to Treat Severe Parkinson Disease in an Elderly Population?
Neurol 68:1345-1355, Derost,P.-P.,et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Gender Differences in Parkinsons Disease
JNNP 78:819-824,787, Haaxma,C.A.,et al, 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Gout and Risk of Parkinson Disease: A Prospective Study
Neurol 69:1696-1700, Alonso,A.,et al, 2007
Parkinson Disease, 10 Years After Its Genetic Revolution: Multiple Clues to a Complex Disorder
Neurol 69:2093-2104, Klein,C. &Schlossmacher,M.G., 2007
Benign Tremulous Parkinsonism
Arch Neurol 63:354-357,321, Josephs,K.A.,et al, 2006
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
Practice Parameter: Diagnosis and Prognosis of New Onset Parkinson Disease (An Evidence-Based Review)
Neurol 66:968-975, Suchowersky,O.,et al, 2006
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006
A Randomized Trial of Deep-Brain Stimulation for Parkinsons Disease
NEJM 355:896-908, Deuschl,G.,et al, 2006
Collaborative Analysis of a-Synuclein Gene Promotor Variability and Parkinson Disease
JAMA 296:661-670, Maraganore,D.M.,et al, 2006
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Occupation and Parkinsonism in Three Movement Disorders Clinics
Neurol 65:1430-1435, Goldman,S.M.,et al, 2005